Physician profile
Louisa Ziglar
NPI 1538336151
$2,681.48
in general payments reported to CMS, 2019-2025
26 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $144 · 2021: $92.24 · 2022: $265 · 2023: $394 · 2024: $194 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.57 |
| Education | $153.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.05 | 2019-2023 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $296.59 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $277.11 | 2021-2024 | Saphnelo |
| Janssen Biotech, INC. | $265.08 | 2019-2025 | Tremfya |
| Amgen INC. | $248.34 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Actelion Pharmaceuticals US, INC. | $173.45 | 2019 | |
| Aurinia Pharma U.S., INC. | $113.40 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $98.59 | 2019 | |
| Pfizer INC. | $96.85 | 2019-2021 | |
| Ucb, INC. | $95.95 | 2019-2023 | Cimzia |
| Radius Health, INC. | $80.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $65.79 | 2019-2025 | Benlysta |
| Merck Sharp & Dohme LLC | $63.31 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $61.09 | 2019 | |
| Celgene Corporation | $44.70 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.06 | 2019 | |
| Depuy Synthes Sales INC. | $30.28 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $17.53 | 2023 | Iovera |
| Hikma Pharmaceuticals USA | $17.22 | 2019 | |
| Genzyme Corporation | $17.09 | 2025 | |
| Mallinckrodt Enterprises LLC | $16.91 | 2019 | |
| Ethicon US, LLC | $16.68 | 2019 | |
| Lundbeck LLC | $16.67 | 2020 | |
| Genentech USA, INC. | $13.90 | 2019 | |
| Horizon Therapeutics Plc | $13.80 | 2019 | |
| Csl Behring | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louisa Ziglar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.